ArticleDrug design, development and therapy2025
Proteome-Wide Mapping of Artesunate Targets Reveals Enrichment of the Ubiquitin-Proteasome System.
Article in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Artesunate (AS) has great pharmacokinetic and clinical value. However, a comprehensive and up-to-date study exclusively focusing on AS direct binding proteins has not yet been conducted. Methods: We performed a systematic, data-driven mapping of AS-binding protein via HuProt™ 20K human proteome microarray. To characterize the biological features of AS-binding proteins through a series of bioinformatic analyses. Results: Firstly, AS targeted ubiquitin-mediated proteolysis, mineral absorption, Salmonella infection and glycolysis/gluconeogenesis. Among them, ubiquitin-mediated proteolysis has highest confidence scores, chaperone complex and ubiquitin-like protein conjugating enzyme activity were enriched in this set. Secondly, we showed that the bioactivity of AS encompasses a multifaceted range of health-promoting effects. Collectively, this study provided a valuable resource for AS-binding proteins. Furthermore, protein biological function is determined by their three-dimensional structure, when a protein fails to fold into its native structure, the proteins undergo mislocalisation/abnormal accumulation/degradation, leading to conformational diseases (CDs). Conclusion: Considering that AS could target ubiquitin-proteasome system (UPS) and encompass a multifaceted range of health-promoting effects, a comprehensive understanding of the regulatory effects of AS on the UPS and its intrinsic mechanisms will enhance its ability to serve as a protective agent to fight against CDs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.